Drug Profile
Nerinetide - Arbor Vita Corporation/NoNO
Alternative Names: NA-1; Tat-NR2B9cLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Arbor Vita Corporation; NoNO
- Developer Arbor Vita Corporation; NoNO; University of Calgary
- Class Peptides; Vascular disorder therapies
- Mechanism of Action PDZ domain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Stroke
- Phase I Traumatic brain injuries
- Preclinical Alzheimer's disease; Anxiety disorders; Epilepsy; Ischaemia; Pain
- No development reported Subarachnoid haemorrhage
Most Recent Events
- 11 Sep 2023 Nerinetide is still in phase III trials for Stroke in USA, Australia, Germany (NCT04462536)
- 31 Aug 2023 NoNo in collaboration with University of Calgary completes a phase III trial for Stroke in USA, Australia, Canada, Germany, Italy, Netherlands, Norway, Singapore, Switzerland (IV) (NCT04462536)
- 27 Mar 2023 NoNO completes the phase III FRONTIER trial for Stoke in Canada (IV) (NCT02315443)